Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
In a recent study published in the journal Science Advances, researchers in Sweden conducted virtual screens of over 16 million compounds using multiple receptor models developed by AlphaFold and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results